RARE vs BRVE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RARE · Ultragenyx Pharmaceutical$15.43 ▼ 0.90%
BRVE · Braveheart Bio$18.60 ▲ 6.80%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RARE -40.2%
- BRVE -37.6%
Head to head
| Metric | RARE | BRVE |
|---|---|---|
| Price | $15.43 | $18.60 |
| Change today | ▼ 0.90% | ▲ 6.80% |
| Market cap | $1.57B | $1.67B |
| Return, 3 months | -42.4% | -32.4% |
| Return, year to date | -32.9% | – |
| Return, 1 year | -49.6% | – |
| P/E (TTM) | -3.0 | -3.0 |
| P/B | -4.2 | -17.5 |
| P/E percentile vs own 5y | 97th | 59th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +28.1% | – |
| Net profit growth (YoY) | +20.0% | -3,833.9% |
| Gross margin | 83.1% | – |
| Operating margin | -73.6% | – |
| Net margin | -81.7% | – |
| Return on equity | – | – |
| Analyst target vs. price | +84.2% | +143.3% |
| Analyst buy share | 50% | 100% |
| RSI (14) | 45 | 39 |
| 30-day volatility | 54.6% | 78.6% |
| Max drawdown, 1 year | -64.8% | -41.9% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BRVE is the largest of the group by market value.
- BRVE carries the lowest trailing P/E.
- RARE has been the calmest stock over the last 30 days.